Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is just a waste of time! adios
we have two different ideas!
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
https://meetings.asco.org/abstracts-presentations/218505
go back to the cave!
your words mean nothing
Moderna said during its investor call that it was starting a Phase 3 confirmatory study, which it hoped to open in the third quarter of this year.
Scientists have been chasing the dream of vaccines to treat cancer for decades with few successes. Experts say mRNA vaccines, which can be produced in as little as eight weeks, paired with drugs that rev up the immune system may lead to a new generation of cancer therapies--------
cancer- mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65%
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
Adverse events reported with mRNA-4157 (V940) in KEYNOTE-942 were consistent with those previously observed in a Phase 1 clinical trial. The safety profile of KEYTRUDA was consistent with findings from previous studies. The number of patients reporting treatment related Grade = 3 adverse events were similar between the arms (25% vs 18%, respectively). The most common adverse events of any grade attributed to either mRNA-4157 (V940) or the combination of mRNA-4157 (V940) and KEYTRUDA were fatigue (60.6%), injection site pain (55.8%) and chills (50.0%).
https://investors.modernatx.com/news/news-details/2023/Moderna-and-Merck-Announce-mRNA-4157-V940-in-Combination-With-KEYTRUDAR-pembrolizumab-Demonstrated-a-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-F/default.aspx
Tang bought 30% of the float...
Planned MANTRA-2 clinical update at a medical conference in 4Q 2023
PHASE 2- it works very well
Milademetan Shows Early Activity in MDM2-Amplified Advanced Solid Tumors
Notably, activity with the MDM2 inhibitor was observed in patients with heavily pretreated, refractory disease.
more news to come:
Evaluate avenues to enhance the pipeline through precision oncology program acquisition-
$RAIN 36.4 million shares of common stock outstanding
Year-end 2023 cash guidance of $75-$80 million, and cash runway to year-end 2026
There's one piece left-- Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -
At the data cutoff of October 26, 2022, 17 patients were enrolled. Two unconfirmed partial responses were observed in patients with pancreatic and lung cancer with a tumor regression of 34% and 30% with lung cancer, respectively. Additionally, there was promising tumor regression of 29% in a patient with biliary tract cancer and 27% in a patient with breast cancer; both are receiving continued investigational therapy.
https://www.rainoncology.com/news-press-releases/rain-therapeutics-provides-interim-analysis-of-phase-2-basket-trial-of-milademetan-for-mdm2-amplified-advanced-solid-tumors-mantra-2
NEW$$$$-Tang Capital Partners Lp ownership in RAIN / Rain Oncology Inc
2023-06-01 - Tang Capital Partners Lp has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,740,341 shares of Rain Oncology Inc (US:RAIN). This represents 14.1 percent ownership of the company.
https://fintel.io/so/us/rain/tang-capital-partners-lp
Oxford Properties Completes US$91M Sale of Newly Constructed, 140,000 Square Foot Boston GMP Facility to Pioneering Biotechnology Firm Moderna
https://www.bldup.com/posts/oxford-properties-completes-us-91m-sale-of-newly-constructed-140-000-square-foot-boston-gmp-facility-to-pioneering-biotechnology-firm-moderna
Doctors say this is the most important virus you’ve never heard of-there's no vaccine for HMPV, nor is there an antiviral drug to treat it.
https://edition.cnn.com/2023/05/29/health/human-metapneumovirus-explainer-wellness/index.html
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Phase-2-Data-on-mRNA-4157-V940-an-Investigational-Individualized-Neoantigen-Therapy-to-be-Presented-at-the-2023-ASCO-Annual-Meeting/default.aspx
BEIJING, May 26 (Reuters) - U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy.
The U.S. pharmaceutical and biotech firm registered a unit called Moderna (China) Biotech Limited in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha.
"We are exploring opportunities to engage in the market and bring the power of Moderna’s mRNA platform to the people of China," a spokesperson said in response to a query from Reuters.
The company prior to this had no presence in mainland China. It opened an office in Hong Kong last year as part of an Asia expansion.
Its establishment of a mainland China unit comes as its revenue growth slows sharply due to waning global demand for its COVID vaccine, the U.S. company's only approved product.
The company in February forecast a possible net loss for 2023, calling it a transition year before it starts to see sales from experimental vaccines for respiratory syncytial virus (RSV) and flu.
Those vaccines, based on the same mRNA platform as its COVID shot, have yet to be filed for regulatory approval decisions.
Moderna has said that it was keen to sell its mRNA vaccine to China but the company and its foreign peers have so far been kept out as Beijing has insisted on using only Chinese-made COVID-19 vaccines for its population.
CEO Stephane Bancel visited Shanghai last month during which he said Moderna will accelerate its investment in Shanghai and work with Chinese partners on local research, development, according to local media Yicai Global.
Globe-trotting Moderna is investing $322M in new manufacturing site close to home:
The move comes as Moderna is rapidly growing. The company plans to add 2,000 employees this year, bringing its head count to 6,000.
https://www.fiercepharma.com/manufacturing/globetrotting-moderna-investing-322m-new-manufacturing-site-close-home
your extinction as a human being, you are living in the world of fairy tales!
$MRNA
Moderna has early clinical evidence that its mRNA technology can treat a rare disease by replacing intracellular proteins. Participants in the phase 1/2 trial experienced a 66% overall relative risk reduction in the frequency of life-threatening events, encouraging the biotech to keep studying the candidate.
The phase 1/2 trial marks the first time a biotech has reported clinical data on an mRNA therapeutic for intracellular protein replacement. In the study, children with propionic acidemia (PA), a rare inherited metabolic disorder, received multiple doses of a lipid nanoparticle-encapsulated dual mRNA therapy.
Moderna’s therapy, mRNA-3927, encodes two subunit proteins, PCCA and PCCB, that form the enzyme that is deficient in patients with PA. By triggering production of the subunit proteins, Moderna could fix the root cause of the disease and prevent the buildup of harmful compounds that cause PA symptoms.
https://www.fiercebiotech.com/biotech/moderna-looking-past-vaccines-guides-first-mrna-protein-replacement-therapy-past-early
Moderna,Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), presented at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting.
More than 280 doses of mRNA-3927 were administered. Five patients have more than a year of dosing
https://investors.modernatx.com/news/news-details/2023/Phase-12-Interim-Data-on-Modernas-mRNA-3927-an-Investigational-mRNA-Therapy-for-Propionic-Acidemia-PA-Presented-at-the-2023-ASGCT-Annual-Meeting/default.aspx
AI dramatically improved mRNA vaccines in just 11 minutes:
https://www.freethink.com/health/mrna-sequence
Is Moderna Building a Respiratory Vaccine Empire: I agree 1000%
https://www.fool.com/investing/2023/05/06/is-moderna-building-a-respiratory-vaccine-empire/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Moderna rakes in surprise profits ahead of 400% vaccine price hike
Moderna made about $680 million more than expected in the first quarter.
https://arstechnica.com/science/2023/05/moderna-rakes-in-surprise-profits-ahead-of-400-vaccine-price-hike/
Moderna Jumps On Unexpected First-Quarter Profit Amid Plummeting Covid Sales
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Phase-12-Data-on-mRNA-3927-an-Investigational-mRNA-Therapy-for-Propionic-Acidemia-PA-to-be-Presented-at-the-2023-ASGCT-Annual-Meeting/default.aspx
"We are pleased to expand our footprint into the Philipines by establishing an Enterprise Solutions Hub and commercial operations. The Philippines has a critical mix of talent and global business service expertise, which makes it an excellent location to scale efficiently and provide regional support," said Stéphane Bancel, Chief Executive Officer of Moderna."The Asia Pacific region is integral to Moderna's business, with established subsidiaries in Australia, Hong Kong, Japan, Singapore, South Korea, and Taiwan. We look forward to further solidifying our presence. The addition of the Philippines site completes our strategy to provide regional solutions across the business, complementing our existing locations in Atlanta, Georgia, which services the Americas, and Warsaw, Poland, which covers Europe, the Middle East, and Africa."
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Establishment-of-an-Enterprise-Solutions-Hub-and-Commercial-Operations-in-The-Philippines/default.aspx
shrimp for everyone!
Moderna looks to the future with latest campaign and a flashy new ad
Cathie Wood's ARK Innovation ETF buys shares of businesses that have the potential to change our world: $MRNA
https://www.fool.com/investing/2023/04/30/this-cathie-wood-stock-is-tanking-heres-why/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
winner$
the important thing is to believe not to hope!
Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects:
https://www.ft.com/content/5fc71e17-541c-4fe8-a2cb-ae7d17917366?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
For my second pick, I'm swinging for the fences with a long shot to surpass Berkshire Hathaway. Moderna is a biotech company that most people know for its COVID-19 vaccine.
However, the company's messenger RNA therapeutics and vaccines can potentially be used to treat other diseases. In fact, Moderna's chief medical officer, Dr. Paul Burton, recently noted that the company aims to produce vaccines targeting cancer, heart disease, and other serious diseases by 2030. If that prediction comes true, expect Moderna shares to skyrocket.
Before you know it, these three companies might surpass Berkshire Hathaway:
And Moderna shares will need to skyrocket if the company's market cap is going to exceed Berkshire Hathaway's. Today, Moderna has a market cap of $52.8 billion, ranking No. 304 among American companies. To catch Berkshire, Moderna would need to grow 14 times. That's a big ask, but effective treatments for life-threatening diseases like cancer and heart disease would be a game changer, not just for the company -- but for the world.
However, at present, those treatments remain out of reach, meaning Moderna will have to rely on other products to drive its revenue and earnings. Financially, the company remains healthy, with $18.9 billion in revenue and $9.4 billion in operating income over the last 12 months. Yet, with sales of its COVID vaccine waning, analysts expect revenue to decline by 60% in 2023 and a further 15% in 2024.
Needless to say, owning Moderna isn't for everyone. Like a power hitter at the plate, Moderna is swinging for the fences. Sometimes those hitters blast it out of the park; other times, they strike out.
I agree 1000%>>>>>>>>>>
https://www.fool.com/investing/2023/04/27/3-stocks-that-could-be-worth-more-than-berkshire-h/
I find value in your desperation....over thinking!
Florida surgeon general altered Covid-19 vaccine analysis to suggest higher risk for younger men:
https://edition.cnn.com/2023/04/25/health/florida-covid-vaccine-analysis-ladapo/index.html
Construction commences at Moderna Innovation and Technology Centre in the UK
https://www.harwellcampus.com/moderna-groundbreaking-at-harwell/
Moderna and IBM-
today announced an agreement under which Moderna will explore next generation technologies including quantum computing and artificial intelligence to advance and accelerate mRNA research and science.
https://investors.modernatx.com/news/news-details/2023/Moderna-and-IBM-to-Explore-Quantum-Computing-and-Generative-AI-for-mRNA-Science/default.aspx
RSV vaccine approval should be a top priority for the FDA.. I agree 100%
https://www.statnews.com/2023/04/19/rsv-vaccines-children-fda-approval/